70.49
price down icon0.28%   -0.20
after-market Handel nachbörslich: 70.49
loading

Incyte Corp Aktie (INCY) Neueste Nachrichten

pulisher
Jul 24, 2025

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - Insider Monkey

Jul 24, 2025
pulisher
Jul 24, 2025

Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

What drives Incyte Corporation stock priceRapid capital growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 17, 2025

Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK

Jul 16, 2025
pulisher
Jul 16, 2025

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff

Jul 15, 2025
pulisher
Jul 14, 2025

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma Settles Incyte Corp Litigation - Rediff

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma settles litigation with Incyte Corp - Press Trust of India

Jul 14, 2025
pulisher
Jul 11, 2025

Incyte discloses new bicyclooctane KRAS inhibitors - BioWorld MedTech

Jul 11, 2025
pulisher
Jul 10, 2025

Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte to Report Second Quarter Financial Results - Business Wire

Jul 10, 2025
pulisher
Jul 09, 2025

William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey

Jul 09, 2025
pulisher
Jul 06, 2025

Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo

Jul 06, 2025
pulisher
Jul 03, 2025

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha

Jul 03, 2025
pulisher
Jul 02, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 02, 2025
pulisher
Jun 30, 2025

Meury named Incyte CEO as Hoppenot departs - Delaware Business Times

Jun 30, 2025
pulisher
Jun 30, 2025

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran” - Insider Monkey

Jun 30, 2025
pulisher
Jun 27, 2025

Incyte Corporation (INCY) Announces Leadership Transition with N - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Bill Meury Takes Helm at Incyte (INCY) as New CEO | INCY Stock N - GuruFocus

Jun 27, 2025
pulisher
Jun 26, 2025

Incyte Appoints Bill Meury Chief Executive Officer - Contract Pharma

Jun 26, 2025
pulisher
Jun 26, 2025

Citi reiterates buy rating on Incyte stock amid CEO transition - Investing.com

Jun 26, 2025
pulisher
Jun 24, 2025

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN

Jun 24, 2025
pulisher
Jun 24, 2025

How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com

Jun 24, 2025
pulisher
Jun 23, 2025

Incyte stock falls after FDA extends review of pediatric eczema cream - Investing.com

Jun 23, 2025
pulisher
Jun 22, 2025

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call - Yahoo Finance

Jun 22, 2025
pulisher
Jun 20, 2025

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis - Business Wire

Jun 20, 2025
pulisher
Jun 19, 2025

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Jun 16, 2025
pulisher
Jun 16, 2025

Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Alopecia Areata Market Expected to Experience Major Growth - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada

Jun 16, 2025
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):